Collegium Pharmaceutical, Inc. Increase (Decrease) in Deferred Revenue
Collegium Pharmaceutical, Inc. (COLL) reported Increase (Decrease) in Deferred Revenue of -$4.94 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-07
- Collegium Pharmaceutical, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$10.36M, a 86441.67% decline year-over-year.
- Collegium Pharmaceutical, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was $1.67M.
- Collegium Pharmaceutical, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $3.75M.
- Collegium Pharmaceutical, Inc. increase (decrease) in deferred revenue for fiscal 2017 was -$4.94M, a 200.00% decline from fiscal 2016.
- Collegium Pharmaceutical, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $4.94M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$10.36M derived: sum of 2 quarters · filed 2018-03-07 | -$8.70M derived: sum of 3 quarters · filed 2018-03-07 | -$4.94M 10-K · filed 2018-03-07 |
| 2017-09-30 | -$10.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$8.70M derived: sum of 2 quarters · filed 2017-11-08 | -$4.94M 10-Q · filed 2017-11-08 | -$3.94M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.42M 10-Q · filed 2017-08-09 | $6.42M derived: sum of 3 quarters · filed 2018-03-07 | $6.43M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $3.75M 10-Q · filed 2017-05-10 | $4.76M derived: sum of 2 quarters · filed 2018-03-07 | $4.77M derived: sum of 3 quarters · filed 2018-03-07 | |
| 2016-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.02M derived: sum of 2 quarters · filed 2018-03-07 | $4.94M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.94M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $3.93M 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |